PDC*line Pharma President & CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June
PDC*line Pharma is pleased to announce that Eric Halioua, PDC*line Pharm’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a virtual event, will be held on June 25 - 26, 2020.
Details of PDC*line Pharma’s oral presentation are the following:
Event: 3rd Annual Next-Gen Immuno-Oncology Congress
Date: June 25, 2020
Time: 14:05 Eastern Time
Title: New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)
• PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
• PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint
About Next-Gen Immuno-Oncology Congress
The 3rd Annual Next-Gen Immuno-Oncology Congress provides an opportunity for experts in the field to discuss the latest in antibodies, cellular therapy and immune-checkpoint research, learn of the new case studies of immuno-oncology projects in development, and contribute to interactive Q&A sessions with their peers to deliberate key topics of relevance, explore the latest platforms and technologies on the market for development, and discuss the best tools for their research in immuno-oncology.
